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Iron deﬁciency anaemia represents a major public health problem, particularly in infants, young children, pregnant women, and
females with heavy menses. Oral iron supplementation is a cheap, safe, and eﬀective means of increasing haemoglobin levels and
restoring iron stores to prevent and correct iron deﬁciency. Many preparations are available, varying widely in dosage, formulation
(quick or prolonged release), and chemical state (ferrous or ferric form). The debate over the advantages of ferrous versus ferric
formulations is ongoing. In this literature review, the tolerability and eﬃcacy of ferrous versus ferric iron formulations are
evaluated. We focused on studies comparing ferrous sulphate preparations with ferric iron polymaltose complex preparations,
the two predominant forms of iron used. Current data show that slow-release ferrous sulphate preparations remain the established
and standard treatment of iron deﬁciency, irrespective of the indication, given their good bioavailability, eﬃcacy, and acceptable
tolerability demonstrated in several large clinical studies.
1.Introduction
Iron deﬁciency anaemia (IDA) is the condition in which
there is anaemia due to a lack of iron. IDA develops when
available iron is insuﬃcient to support normal red cell
production and is the most common type of anaemia [1].
AccordingtotheWorldHealthOrganisation(WHO)[2],
iron deﬁciency is the most common form of malnutrition
in the world, aﬀecting around 2 billion people worldwide,
which corresponds to 25% of the population globally. Iron
deﬁciency is highly prevalent in developing countries where
it represents a major public health problem, but it is also
common in Western countries, particularly in populations
such as infants, young children, women with heavy menses,
and pregnant and puerperal women [3]. Women are at high
risk of developing IDA during pregnancy due to increased
iron requirements [4, 5]. Iron deﬁciency anaemia indepen-
dently increases morbidity and mortality [6]. In France, a
large epidemiological study (SUVIMAX trial) [7] has shown
that approximately 93% of women have insuﬃcient dietary
iron intake and 23% of women of reproductive age are iron
deﬁcient, 4% of whom are anaemic.
Common causes of iron deﬁciency include inadequate
intake of dietary iron, inadequate iron utilisation during
chronic and inﬂammatory diseases, impaired iron absorp-
tion, or excess iron loss. In the vast majority of cases, the
cause of iron deﬁciency anaemia results in an anaemia that
is both avoidable and reversible by increasing iron sup-
plementation or reducing iron loss.
Iron is essential for oxygen transport and cell growth
and survival. The typical adult human body contains an
average of 3.5g of iron (approximately 4g for males and 3g
for females). Most of the iron within the body is used in
haemoglobin (2.1g). A small amount is devoted to cellular
protein synthesis (myoglobin, cytochromes) or circulates
through plasma bound to transferrin [7]. Iron homeostasis
is closely regulated via intestinal absorption and by recycling
of iron already present in the body. This element has the
particularity that once absorbed, there is no physiologic
mechanismforitsexcretionfromthebody.Only1mgofiron
is lost per day by males and 2mg by menstruating females
(through blood and mucosal epithelial cell loss).
Tomaintainadequatesuppliesofironforhemesynthesis,
20mg of iron is recycled daily, going from senescent red2 The Scientiﬁc World Journal
Table 1: Diﬀerences between bivalent and trivalent oral iron preparations.
Iron supplement Comments
Bivalent
Ferrous fumarate (Fe2+)
More adverse eﬀects if not in a prolonged-release formulation Ferrous gluconate (Fe2+)
Ferrous sulphate (Fe2+)
Ferrous glycine sulphate (Fe2+)
Trivalent Poorer absorption
Iron protein succinylate (Fe3+)M o r e e x p e n s i v e
Iron polymaltose complex (Fe3+) A greater number of intakes
cells that are removed from the circulation to new cells in
the bone marrow [8]. Iron from older cells is loaded onto
transferrin by macrophages for delivery to the bone marrow.
The diet provides 10–20mg per day of iron requirement,
as heme (mainly in red meat) and nonheme (white meat,
vegetables,andcereals).Healthyadultsabsorbapproximately
10 to 15% of this iron in their diet, but absorption is
inﬂuenced by the body’s iron stores, the type of iron in the
diet (heme and nonheme), and other dietary factors that
may increase or reduce the absorption of iron. Heme iron
is absorbed very eﬃciently by the body whereas only 1 to
7% of nonheme iron is absorbed [9]. Because nonheme iron
i sp r e s e n tm a i n l ya sf e r r i ci r o ni nf o o d ,i tm u s tb er e d u c e d
to the ferrous and divalent form (Fe2+)p r i o rt ou p t a k eb y
intestinal enterocytes [10]. Around 1-2mg/day of additional
dietary is needed to balance losses in the urine, sweat, and
stools. The hormone hepcidin regulates iron homeostasis
by controlling ferroportin-mediated release of iron from
enterocytes and macrophages [11].
For the treatment of iron deﬁciency anaemia, current
guidelines recommend the dose of 60 to 120mg of elemental
iron of ferrous sulphate per day for a minimum duration
of 3 months in adolescents and adults, including pregnant
women [12]. Given that it is diﬃcult to satisfy the increased
iron requirement during pregnancy by dietary means [13],
most international health organisations [14] and national
authorities recommend oral iron supplementation during
pregnancy. The recommended dose for the prevention of
iron deﬁciency anaemia during pregnancy is generally 60mg
of elemental iron per day to be taken during pregnancy and
for the 6 months postpartum for pregnant women who did
not begin iron supplementation in the second trimester of
the pregnancy [15]. International organisations including
WHO and UNICEF recommend oral iron supplementation
for young children and adolescents in countries where the
prevalence of anaemia in the population is over 40% [16].
In the case of iron deﬁciency anaemia, once the underly-
ing cause has been identiﬁed and treated, iron replacement
therapy is necessary to correct haemoglobin levels and
replenish iron stores. From a practical point of view, the oral
routeistheﬁrstchoicetoreplaceironstoresasthisallowsthe
normal mechanism of absorption to be used and thus may
prevent complications and the risk of iron overload, such as
isreportedwithintravenousironadministration, inaddition
to being an inexpensive and eﬀective treatment. Many
oral iron preparations are available, the most frequently
used being ferrous sulphate (FS) and ferric preparations
with an iron polymaltose complex (IPC). Most of these
preparationsvaryintheirbioavailability,eﬃcacy,sideeﬀects,
and cost. Here we review the data available in the literature
with regard to the eﬃcacy and tolerability of ferric and
ferrous preparations currently used in clinical practice, and
especially sustained-release FS versus IPC which are among
the most prescribed iron formulations in the world.
2.BioavailabilityandTherapeutic Efﬁcacyof
Bivalentand TrivalentIronPreparations
The iron-containing preparations available on the market
vary widely in dosage, salt, and chemical state of iron
(ferrous or ferric form) contained in the preparation, as well
as the galenic form (quick and prolonged release). However,
in clinical practice bivalent iron salts such as FS, ferrous
gluconate, and ferrous fumarate are more widely used and
are preferred over ferric iron preparations [17, 18], as re-
commended by the WHO [19]. FS preparations usually
present good bioavailability (between 10 and 15%), while
bioavailability of iron ferric preparations is 3 to 4 times
less than that of conventional FS [20]. This is due to the
extremely poor solubility of ferric iron in alkaline media
and the fact that ferric iron needs to be transformed into
f e r r o u si r o nb e f o r eb e i n ga b s o r b e d( Table 1). Among ferrous
preparations, FS remains the established and the standard
treatment of iron deﬁciency given its acceptable tolerability,
high eﬀectiveness, and low cost.
Advancesinoralpreparationhaveledtothedevelopment
of prolonged-release preparations with new galenic formu-
lations that may improve gastrointestinal tolerability and
enhance the bioavailability. Among these compounds, the
most studied and prescribed is Tardyferon,ap r o l o n g e d -
release ferrous sulfate tablet containing 80mg of elemental
iron. In this product a polymeric complex surrounds Fe2+
ions forming a matrix that controls the availability of
Fe2+ ions to the individual sections of the gastrointestinal
tract in conformity with their absorptive capacity. After
its absorption, iron levels in the blood reach a maximum
after about 7 hours and remain elevated for 24 hours. In a
study conducted by Kaltwasser et al. [21], the bioavailability
of Tardyferon was compared to that of a quick-release
ferrous ascorbate preparation in 18 healthy phlebotomizedThe Scientiﬁc World Journal 3
volunteers,usingastable 54Feironisotope.Thestudydidnot
ﬁnd any diﬀerence in iron intestinal absorption measured
on day 21 between the two preparations. Moreover, after
two months of treatment, haemoglobin levels increased to
approximately baseline values in both treatment groups.
Maltofer/Ferrum Hausmann/Ferranina is a triva-
lent oral iron (100mg of element iron) coupled with sugar
complexes (IPC). This structure is believed to give the ferric
iron compound a better stability and portability of ferric
iron ions through the intestinal mucosa under physiological
conditions, compared to conventional ferric compounds
[22]. While some reports indicated that the availability of
iron from IPC for haemoglobin synthesis is comparable to
that of conventional ferrous salts such as FS [23–25], many
studies have reported poor eﬀectiveness of iron from ferric
polymaltose complex [26–30]. Mehta was the ﬁrst to publish
individual clinical case reports of patients failing to respond
to IPC [25, 26]. In 2003, Mehta [31] published a report of 27
patients with iron deﬁciency anaemia who failed to respond
to IPC given for 4 to 52 weeks and showed that the same
patientsresponded totheadministration offerrousfumarate
for 4 to 13 weeks. Similar data was obtained by Ruiz-
Arg¨ uelles et al. [30] who showed that among 240 patients
diagnosed with iron deﬁciency anaemia in his institution
and treated with oral IPC, 75 (31%) failed to respond.
Median haemoglobin levels when the patients were referred
for the study after being given oral IPC was 10.3g/dL. After
administration oral ferrous fumarate during periods ranging
from 1 to 14 months, haemoglobin levels rose to a median of
12.5g/dL (P<0.01).
Kaltwasseretal.[32]alsocomparedtrivalentversusbiva-
lent preparations and showed a signiﬁcant diﬀerence in the
bioavailability of 59Fe III hydroxide-polymaltose compared
to that of 59Fe labeled-bivalent iron preparations (ferrous
ascorbate or a quick-release FS preparation). Intestinal iron
absorption in the fasting state, as measured by 59Fe whole
body retention and simultaneous estimation of plasma iron
tolerance curves, was low for the Fe III complex (1.2 ± 0.1%)
ascomparedtoferrousascorbate(43.7 ±7.1%).Afterameal,
the absorption of the divalent preparation was not aﬀected,
whereas that of the Fe III complex increased to 8.8 ± 4.7%.
However the daily increase in haemoglobin concentrations
after an equivalent therapeutic dose of 100mg elemental
iron during 28 days was greater for the divalent preparations
compared to the Fe III hydroxide-polymaltose complex (1.1
± 0.3g/L versus 0.68 ± 0.2g/L). Similar observations were
reported by Malhotra et al. [33] and Heinrich et al. [34]o n
the poor bioavailability of the trivalent preparations. Nielsen
et al. [35] found no haemoglobin increase in 9 patients
receiving 100 to 300mg of ferric polymaltose complex on
an empty stomach during a 4-week treatment period. On
the other hand, subsequent treatment with ferrous sulphate
(100–200mg Fe/day) resulted in a signiﬁcant increase of
haemoglobin (0.15–0.23g/dL per day). In another study
conducted by Nielsen et al. [36], 33 patients with chronic
haemorrhagic iron deﬁciency anaemia (Hb <12g/dL, serum
ferritin <12µg/dL) received Tardyferon (1 tablet/day) over
6 to 10 weeks. Signiﬁcant increases in haemoglobin and
ferritin concentrations were observed within this period
(mean Hb increased from 10.2 ± 1.6t o1 2 .5 ± 1.5g/dL;
ferritin, from 9 ± 11 to 31 ± 23µg/L), indicating that
speciﬁc prolonged-release iron preparations may provide
relatively high iron bioavailability and are eﬀective in the
treatment of iron deﬁciency anaemia, even in the case of
chronic haemorrhage. Only one blinded, double-dummy
randomisedtrialconductedbyLangstaﬀetal.[37]c ompar ed
the eﬃcacy and tolerability of IPC preparations (Ferrum
Hausmann, 200mg elemental iron/day) to standard FS
preparations (180mg elemental iron/day). Both were given
to 126 adult patients during 9 weeks. FS resulted in a
signiﬁcantlyhigherincreasein haemoglobinlevels compared
to Ferrum Hausmann a t3a n d6w e e k s .A tw e e k9
the diﬀerence between both groups was not statistically
signiﬁcant.
Other ﬁndings concerning the lack of eﬃcacy of IPC
versusFSwerereportedinstudiesonriskgroupsforanaemia
as children, pregnant women, and the elderly. Two large
randomised trials assessed the eﬃcacy and tolerability of
iron polymaltose complex versus FS, in the treatment of
iron deﬁciency anaemia in children. The ﬁrst study [38]
was conducted in 118 children who were randomised to
receive either oral IPC or oral FS at an equal dose of
6mg/kg/day, on an empty stomach for one month. The
increase of haemoglobin one month after the start of the
therapy was signiﬁcantly higher in the group of children
having received FS (9.44±0.67g/dL) compared to the group
of patients treated with IPC (8.67 ± 0.73g/dL). In addition,
approximately 21% of the children in the IPC group had
decreased haemoglobin levels after treatment compared to
baseline values. Lack of eﬀectiveness of IPC in children
was also reported by Haliotis and Papanastasiou in 100
anaemic children receiving 4mg/kg/day of iron for a 2-
month treatment period [39]. The eﬃcacy of IPC in the
treatment of iron deﬁciency anaemia during pregnancy has
not been well established, and conﬂicting results have been
reported [40–42]. On the other hand, a daily dose of 80mg
of elemental iron contained in one tablet of the preparation
Tardyferon was shown to be suﬃcient for recovery of
iron reserves within the puerperium period, as shown by
M´ ara et al. [43]. In elderly patients with iron deﬁciency,
similar ﬁndings of poor eﬀectiveness of IPC were reported
by Sanders [44].
3. Tolerability of Ferrous versus
FerricIron Preparations
Sideeﬀectsoforalirontherapyareacommonprobleminthe
treatment of patients with iron deﬁciency. Gastrointestinal
disturbances such as nausea, heartburn, pain, constipation,
and diarrhoea are the most commonly reported side eﬀects,
irrespective of the type of iron preparation. This occasional
intolerance is usually viewed as a limiting factor for oral iron
therapy, as it may impact patient compliance. The incidence
of the gastrointestinal side eﬀects seems to be generally
associated with the use of unnecessary high doses of iron as
reported by several authors [45, 46]. High iron doses may be
necessary in the case of anaemia.4 The Scientiﬁc World Journal
Incidence of gastrointestinal side eﬀects has been shown
to be lower with controlled-release iron formulations com-
pared to conventional ferrous salt preparations in three large
controlled randomised studies [47–49]. In such formula-
tions, iron is released at a slower rate because of action of
gastric acid on the matrix containing FS, thus reducing the
bolus load of iron into the gastrointestinal tract, hence pro-
ducing fewer side eﬀects. In a systemic review of 106 studies
published up to 2008, including data from 10,515 patients
treated with various oral iron preparations, Manasanch et
al. [50] found that sustained-release FS (Tardyferon)h a d
a statistically signiﬁcant lower incidence of gastrointestinal
events (3.7%) compared to other FS preparations (31.6%),
ferrous fumarate (44.8%), and to preparations containing
ferric iron such as iron protein succinylate (7.0%). The
results of this study demonstrated clearly that sustained
FS release preparations are better tolerated than other
preparations including ferric iron preparations.
In the Langstaﬀ et al. [37] study mentioned above (bio-
availability/eﬃcacy section) that compared IPC preparations
and standard FS preparations given at equivalent therapeutic
doses to 126 patients, adverse events were reported in 12 pa-
tients(22%)treatedwithFerrumHausmann and14(25%)
patients in the standard FS group. The majority of events
were gastrointestinal in nature: constipation was reported in
18% of patients in the Ferrum Hausmann group versus
11% in the standard FS group and abdominal pain in 10%
of patients in the Ferrum Hausmann group versus 18% in
the standard FS group.
4. Conclusion
Oral iron supplementation is the standard treatment for pa-
tients with iron deﬁciency. Ferrous salts and in particular
prolongedreleaseFSpreparationsarethetreatmentofchoice
given their high eﬀectiveness, acceptable tolerability, and
low cost. Preparations with iron III hydroxide polymaltose
generally display poorer bioavailability and their clinical
eﬃcacy is yet to be established. The claimed superiority of
ferric iron preparations over sustained-release ferrous sul-
phate preparations is also questionable. Only preparations
for which eﬃcacy and tolerability have been proven should
be used in the treatment of iron deﬁciency.
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